DuttaP, ChaudetKM, NazarianRM, KroshinskyD, NigwekarSU: Correlation between clinical and pathological features of cutaneous calciphylaxis. PLoS One14: e0218155, 2019PubMed
DuttaP, ChaudetKM, NazarianRM, KroshinskyD, NigwekarSU: Correlation between clinical and pathological features of cutaneous calciphylaxis. PLoS One 14: e0218155, 2019PubMed)| false
ColbocH, MogueletP, BazinD, CarvalhoP, DilliesAS, ChabyG, et al.; Groupe Angio-Dermatologie of the French Society of Dermatology: Localization, morphologic features, and chemical composition of calciphylaxis-related skin deposits in patients with calcific uremic arteriolopathy. JAMA Dermatol155: 789–796, 2019PubMed
ColbocH, MogueletP, BazinD, CarvalhoP, DilliesAS, ChabyG, et al.; Groupe Angio-Dermatologie of the French Society of Dermatology: Localization, morphologic features, and chemical composition of calciphylaxis-related skin deposits in patients with calcific uremic arteriolopathy. JAMA Dermatol 155: 789–796, 2019PubMed)| false
BrandenburgVM, KramannR, RotheH, KaeslerN, KorbielJ, SpechtP, et al.: Calcific uraemic arteriolopathy (calciphylaxis): Data from a large nationwide registry. Nephrol Dial Transplant32: 126–132, 2017PubMed
BrandenburgVM, KramannR, RotheH, KaeslerN, KorbielJ, SpechtP, et al.: Calcific uraemic arteriolopathy (calciphylaxis): Data from a large nationwide registry. Nephrol Dial Transplant 32: 126–132, 2017PubMed)| false
NigwekarSU, ZhaoS, WengerJ, HymesJL, MadduxFW, ThadhaniRI, et al.: A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol27: 3421–3429, 2016PubMed
NigwekarSU, ZhaoS, WengerJ, HymesJL, MadduxFW, ThadhaniRI, et al.: A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol 27: 3421–3429, 2016PubMed)| false
McCarthyJT, El-AzharyRA, PatzeltMT, WeaverAL, AlbrightRC, BridgesAD, et al.: Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc91: 1384–1394, 2016PubMed
McCarthyJT, El-AzharyRA, PatzeltMT, WeaverAL, AlbrightRC, BridgesAD, et al.: Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc 91: 1384–1394, 2016PubMed)| false
BajajR, CourbebaisseM, KroshinskyD, ThadhaniRI, NigwekarSU: Calciphylaxis in patients with normal renal function: A case series and systematic review. Mayo Clin Proc93: 1202–1212, 2018PubMed
BajajR, CourbebaisseM, KroshinskyD, ThadhaniRI, NigwekarSU: Calciphylaxis in patients with normal renal function: A case series and systematic review. Mayo Clin Proc 93: 1202–1212, 2018PubMed)| false
AndersonDC, StewartWK, PiercyDM: Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet2: 323–325, 1968PubMed
AndersonDC, StewartWK, PiercyDM: Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet 2: 323–325, 1968PubMed)| false
NigwekarSU, SolidCA, AnkersE, MalhotraR, EggertW, TurchinA, et al.: Quantifying a rare disease in administrative data: The example of calciphylaxis. J Gen Intern Med29: S724–S731, 2014PubMed
NigwekarSU, SolidCA, AnkersE, MalhotraR, EggertW, TurchinA, et al.: Quantifying a rare disease in administrative data: The example of calciphylaxis. J Gen Intern Med 29: S724–S731, 2014PubMed)| false
NigwekarSU, BhanI, TurchinA, SkentzosSC, HajhosseinyR, SteeleD, et al.: Statin use and calcific uremic arteriolopathy: A matched case-control study. Am J Nephrol37: 325–332, 2013PubMed
NigwekarSU, BhanI, TurchinA, SkentzosSC, HajhosseinyR, SteeleD, et al.: Statin use and calcific uremic arteriolopathy: A matched case-control study. Am J Nephrol 37: 325–332, 2013PubMed)| false
NigwekarSU, NazarianRM: Cutaneous calcification in patients with kidney disease is not always calciphylaxis. Kidney Int94: 244–246, 2018PubMed
NigwekarSU, NazarianRM: Cutaneous calcification in patients with kidney disease is not always calciphylaxis. Kidney Int 94: 244–246, 2018PubMed)| false
JangA, Mark HoMH, YanL: Characterization of risk factors for calciphylaxis in hemodialysis patients in the fraser health renal program: A matched case-control retrospective Review [published online ahead of print Aug 28, 2022. J Pharm Pract doi:10.1177/08971900221118444PubMed
JangA, Mark HoMH, YanL: Characterization of risk factors for calciphylaxis in hemodialysis patients in the fraser health renal program: A matched case-control retrospective Review [published online ahead of print Aug 28, 2022. J Pharm Pract doi:10.1177/08971900221118444PubMed)| false
BrandenburgVM, KramannR, RotheH, et al.: Calcific uraemic arteriolopathy (calciphylaxis): Data from a large nationwide registry. Nephrol Dial Transplant32: 126–132, 2017PubMed
BrandenburgVM, KramannR, RotheH, et al.: Calcific uraemic arteriolopathy (calciphylaxis): Data from a large nationwide registry. Nephrol Dial Transplant 32: 126–132, 2017PubMed)| false
PanchalS, HoltermannK, TrivediN, RegunathH, YerramP: Calciphylaxis: An analysis of concomitant factors, treatment effectiveness and prognosis in 30 patients. Int J Nephrol Renovasc Dis13: 65–71, 2020PubMed
PanchalS, HoltermannK, TrivediN, RegunathH, YerramP: Calciphylaxis: An analysis of concomitant factors, treatment effectiveness and prognosis in 30 patients. Int J Nephrol Renovasc Dis 13: 65–71, 2020PubMed)| false
ZhangY, CorapiKM, LuongoM, ThadhaniR, NigwekarSU: Calciphylaxis in peritoneal dialysis patients: A single center cohort study. Int J Nephrol Renovasc Dis9: 235–241, 2016PubMed
ZhangY, CorapiKM, LuongoM, ThadhaniR, NigwekarSU: Calciphylaxis in peritoneal dialysis patients: A single center cohort study. Int J Nephrol Renovasc Dis 9: 235–241, 2016PubMed)| false
ChinnaduraiR, HuckleA, HegartyJ, KalraPA, SinhaS: Calciphylaxis in end-stage kidney disease: Outcome data from the United Kingdom Calciphylaxis Study. J Nephrol34: 1537–1545, 2021PubMed
ChinnaduraiR, HuckleA, HegartyJ, KalraPA, SinhaS: Calciphylaxis in end-stage kidney disease: Outcome data from the United Kingdom Calciphylaxis Study. J Nephrol 34: 1537–1545, 2021PubMed)| false
HayashiM, TakamatsuI, KannoY, YoshidaT, AbeT, SatoY; Japanese Calciphylaxis Study Group: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant27: 1580–1584, 2012PubMed
HayashiM, TakamatsuI, KannoY, YoshidaT, AbeT, SatoY; Japanese Calciphylaxis Study Group: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012PubMed)| false
LiuY, ZhangX, XieX, YangX, LiuH, TangR, et al.: Risk factors for calciphylaxis in Chinese hemodialysis patients: A matched case-control study. Ren Fail43: 406–416, 2021PubMed
LiuY, ZhangX, XieX, YangX, LiuH, TangR, et al.: Risk factors for calciphylaxis in Chinese hemodialysis patients: A matched case-control study. Ren Fail 43: 406–416, 2021PubMed)| false
GhoshT, WinchesterDS, DavisMDP, El-AzharyR, ComfereNI: Early clinical presentations and progression of calciphylaxis. Int J Dermatol56: 856–861, 2017PubMed
GhoshT, WinchesterDS, DavisMDP, El-AzharyR, ComfereNI: Early clinical presentations and progression of calciphylaxis. Int J Dermatol 56: 856–861, 2017PubMed)| false
TanRYP, JunejaR, GunawardaneDN, MiltonCA: Isolated mesenteric calciphylaxis with ischemic colitis in a hemodialysis patient without active cutaneous calciphylaxis: A case report of calcific uremic arteriolopathy. Kidney Med2: 209–212, 2020PubMed
TanRYP, JunejaR, GunawardaneDN, MiltonCA: Isolated mesenteric calciphylaxis with ischemic colitis in a hemodialysis patient without active cutaneous calciphylaxis: A case report of calcific uremic arteriolopathy. Kidney Med 2: 209–212, 2020PubMed)| false
RiemerCA, El-AzharyRA, WuKL, StrandJJ, LehmanJS: Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: A systematic review. Br J Dermatol177: 1510–1518, 2017PubMed
RiemerCA, El-AzharyRA, WuKL, StrandJJ, LehmanJS: Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: A systematic review. Br J Dermatol 177: 1510–1518, 2017PubMed)| false
DominguezAR: New debates surrounding the histopathological findings of calciphylaxis-do these give us new insights into pathogenesis of the disease?JAMA Dermatol155: 773–775, 2019PubMed
DominguezAR: New debates surrounding the histopathological findings of calciphylaxis-do these give us new insights into pathogenesis of the disease?JAMA Dermatol 155: 773–775, 2019PubMed)| false
NigwekarSU, BlochDB, NazarianRM, VermeerC, BoothSL, XuD, et al.: Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis. J Am Soc Nephrol28: 1717–1722, 2017PubMed
NigwekarSU, BlochDB, NazarianRM, VermeerC, BoothSL, XuD, et al.: Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis. J Am Soc Nephrol 28: 1717–1722, 2017PubMed)| false
Portales-CastilloI, KroshinskyD, MalhotraCK, Culber-CostleyR, CozzolinoMG, KarparisS, et al.: Calciphylaxis-as a drug induced adverse event. Expert Opin Drug Saf18: 29–35, 2019PubMed
Portales-CastilloI, KroshinskyD, MalhotraCK, Culber-CostleyR, CozzolinoMG, KarparisS, et al.: Calciphylaxis-as a drug induced adverse event. Expert Opin Drug Saf 18: 29–35, 2019PubMed)| false
GallowayPA, El-DamanawiR, BardsleyV, PritchardNR, FryAC, OjhaSK, et al.: Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron129: 197–201, 2015PubMed
GallowayPA, El-DamanawiR, BardsleyV, PritchardNR, FryAC, OjhaSK, et al.: Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 129: 197–201, 2015PubMed)| false
RappN, BrandenburgVM, KaeslerN, BakkerSJL, StöhrR, SchuhA, et al.: Hepatic and vascular vitamin K status in patients with high cardiovascular risk. Nutrients13: 3490, 2021PubMed
RappN, BrandenburgVM, KaeslerN, BakkerSJL, StöhrR, SchuhA, et al.: Hepatic and vascular vitamin K status in patients with high cardiovascular risk. Nutrients 13: 3490, 2021PubMed)| false
NigwekarSU, JiramongkolchaiP, WundererF, BlochE, IchinoseR, NazarianRM, et al.: Increased bone morphogenetic protein signaling in the cutaneous vasculature of patients with calciphylaxis. Am J Nephrol46: 429–438, 2017PubMed
NigwekarSU, JiramongkolchaiP, WundererF, BlochE, IchinoseR, NazarianRM, et al.: Increased bone morphogenetic protein signaling in the cutaneous vasculature of patients with calciphylaxis. Am J Nephrol 46: 429–438, 2017PubMed)| false
El-AzharyRA, PatzeltMT, McBaneRD, WeaverAL, AlbrightRC, BridgesAD, et al.: Calciphylaxis: A disease of pannicular thrombosis. Mayo Clin Proc91: 1395–1402, 2016PubMed
El-AzharyRA, PatzeltMT, McBaneRD, WeaverAL, AlbrightRC, BridgesAD, et al.: Calciphylaxis: A disease of pannicular thrombosis. Mayo Clin Proc 91: 1395–1402, 2016PubMed)| false
DobryAS, KoLN, St JohnJ, SloanJM, NigwekarS, KroshinskyD: Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: A case-control study. JAMA Dermatol154: 182–187, 2018PubMed
DobryAS, KoLN, St JohnJ, SloanJM, NigwekarS, KroshinskyD: Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: A case-control study. JAMA Dermatol 154: 182–187, 2018PubMed)| false
PolizzottoMN, BryanT, AshbyMA, MartinP: Symptomatic management of calciphylaxis: A case series and review of the literature. J Pain Symptom Manage32: 186–190, 2006PubMed
PolizzottoMN, BryanT, AshbyMA, MartinP: Symptomatic management of calciphylaxis: A case series and review of the literature. J Pain Symptom Manage 32: 186–190, 2006PubMed)| false
RudermanI, ToussaintND, HawleyCM, et al.: The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. Nephrol Dial Transplant36: 649–656, 2021PubMed
RudermanI, ToussaintND, HawleyCM, et al.: The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. Nephrol Dial Transplant 36: 649–656, 2021PubMed)| false
AdapaS, NaramalaS, GayamV, KoduriNM, DaggubatiSR, PatelP, et al.: Calciphylaxis in a patient on home hemodialysis [published online ahead of print 2020 Jan-Dec]. J Investig Med High Impact Case Rep doi:10.1177/2324709620922718PubMed
AdapaS, NaramalaS, GayamV, KoduriNM, DaggubatiSR, PatelP, et al.: Calciphylaxis in a patient on home hemodialysis [published online ahead of print 2020 Jan-Dec]. J Investig Med High Impact Case Rep doi:10.1177/2324709620922718PubMed)| false
KaleG, JelokaT, ShrividyaS, MulayA, DeshmukhM, KrishnanS, et al.: Calciphylaxis in a renal transplant recipient with normal graft function: A case report and review of literature. Saudi J Kidney Dis Transpl30: 215–220, 2019PubMed
KaleG, JelokaT, ShrividyaS, MulayA, DeshmukhM, KrishnanS, et al.: Calciphylaxis in a renal transplant recipient with normal graft function: A case report and review of literature. Saudi J Kidney Dis Transpl 30: 215–220, 2019PubMed)| false
FloegeJ, KuboY, FloegeA, ChertowGM, ParfreyPS: The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol10: 800–807, 2015PubMed
FloegeJ, KuboY, FloegeA, ChertowGM, ParfreyPS: The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol 10: 800–807, 2015PubMed)| false
MawadHW, SawayaBP, SarinR, MallucheHH: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol52: 160–166, 1999PubMed
MawadHW, SawayaBP, SarinR, MallucheHH: Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52: 160–166, 1999PubMed)| false
HarrisRJ, CropleyTG: Possible role of hypercoagulability in calciphylaxis: review of the literature. J Am Acad Dermatol64: 405–412, 2011PubMed
HarrisRJ, CropleyTG: Possible role of hypercoagulability in calciphylaxis: review of the literature. J Am Acad Dermatol 64: 405–412, 2011PubMed)| false
ZechlinskiJJ, AngelJR: Calciphylaxis in the absence of renal disease: Secondary hyperparathyroidism and systemic lupus erythematosus. J Rheumatol36: 2370–2371, 2009PubMed
ZechlinskiJJ, AngelJR: Calciphylaxis in the absence of renal disease: Secondary hyperparathyroidism and systemic lupus erythematosus. J Rheumatol 36: 2370–2371, 2009PubMed)| false
BarriYM, GravesGS, KnochelJP: Calciphylaxis in a patient with Crohn’s disease in the absence of end-stage renal disease. Am J Kidney Dis29: 773–776, 1997PubMed
BarriYM, GravesGS, KnochelJP: Calciphylaxis in a patient with Crohn’s disease in the absence of end-stage renal disease. Am J Kidney Dis 29: 773–776, 1997PubMed)| false
MalabuUH, RobertsLJ, SanglaKS: Calciphylaxis in a morbidly obese woman with rheumatoid arthritis presenting with severe weight loss and vitamin D deficiency. Endocr Pract17: e104–e108, 2011PubMed
MalabuUH, RobertsLJ, SanglaKS: Calciphylaxis in a morbidly obese woman with rheumatoid arthritis presenting with severe weight loss and vitamin D deficiency. Endocr Pract 17: e104–e108, 2011PubMed)| false
MarhaugG, ShahV, ShroffR, VarsaniH, WedderburnLR, PilkingtonCA, et al.: Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford)47: 1031–1037, 2008PubMed
MarhaugG, ShahV, ShroffR, VarsaniH, WedderburnLR, PilkingtonCA, et al.: Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47: 1031–1037, 2008PubMed)| false
SchaferC, HeissA, SchwarzA, WestenfeldR, KettelerM, FloegeJ, et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest112: 357–366, 2003PubMed
SchaferC, HeissA, SchwarzA, WestenfeldR, KettelerM, FloegeJ, et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357–366, 2003PubMed)| false
RotheH, BrandenburgV, HaunM, KolleritsB, KronenbergF, KettelerM, et al.: Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients: Data from the German Calciphylaxis Registry. PLoS One12: e0172407, 2017PubMed
RotheH, BrandenburgV, HaunM, KolleritsB, KronenbergF, KettelerM, et al.: Ecto-5′ -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients: Data from the German Calciphylaxis Registry. PLoS One 12: e0172407, 2017PubMed)| false
GabelCK, ChakralaT, DobryAS, Garza-MayersAC, KoLN, NguyenED, et al.: The Koebner phenomenon may contribute to the development of calciphylaxis: A case series. JAAD Case Rep13: 57–61, 2021PubMed
GabelCK, ChakralaT, DobryAS, Garza-MayersAC, KoLN, NguyenED, et al.: The Koebner phenomenon may contribute to the development of calciphylaxis: A case series. JAAD Case Rep 13: 57–61, 2021PubMed)| false
McMullenER, HarmsPW, LoweL, FullenDR, ChanMP: Clinicopathologic features and calcium deposition patterns in calciphylaxis: Comparison with gangrene, peripheral artery disease, chronic stasis, and thrombotic vasculopathy. Am J Surg Pathol43: 1273–1281, 2019PubMed
McMullenER, HarmsPW, LoweL, FullenDR, ChanMP: Clinicopathologic features and calcium deposition patterns in calciphylaxis: Comparison with gangrene, peripheral artery disease, chronic stasis, and thrombotic vasculopathy. Am J Surg Pathol 43: 1273–1281, 2019PubMed)| false
BonchakJG, ParkKK, VethanayagamonyT, SheikhMM, WinterfieldLS: Calciphylaxis: a case series and the role of radiology in diagnosis. Int J Dermatol55: e275–e279, 2016PubMed
BonchakJG, ParkKK, VethanayagamonyT, SheikhMM, WinterfieldLS: Calciphylaxis: a case series and the role of radiology in diagnosis. Int J Dermatol 55: e275–e279, 2016PubMed)| false
PaulS, RabitoCA, VedakP, NigwekarSU, KroshinskyD: The role of bone scintigraphy in the diagnosis of calciphylaxis. JAMA Dermatol153: 101–103, 2017PubMed
PaulS, RabitoCA, VedakP, NigwekarSU, KroshinskyD: The role of bone scintigraphy in the diagnosis of calciphylaxis. JAMA Dermatol 153: 101–103, 2017PubMed)| false
ShmidtE, MurthyNS, KnudsenJM, WeenigRH, JacobsMA, StarnesAM, et al.: Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis. J Am Acad Dermatol67: 1296–1301, 2012PubMed
ShmidtE, MurthyNS, KnudsenJM, WeenigRH, JacobsMA, StarnesAM, et al.: Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis. J Am Acad Dermatol 67: 1296–1301, 2012PubMed)| false
AlniemiDT, KannerC, StowmanAM, KnappM, McGevnaL, SewardDJ, et al.: Diagnosing calciphylaxis: A series of cases with both imaging and tissue biopsy [published online ahead of print Jun 8, 2020. J Am Acad doi:10.1016/j.jaad.2020.05.1112020PubMed
AlniemiDT, KannerC, StowmanAM, KnappM, McGevnaL, SewardDJ, et al.: Diagnosing calciphylaxis: A series of cases with both imaging and tissue biopsy [published online ahead of print Jun 8, 2020. J Am Acad doi:10.1016/j.jaad.2020.05.1112020PubMed)| false
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med345: 1119–1124, 2001PubMed
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med 345: 1119–1124, 2001PubMed)| false
BazariH, JaffMR, MannstadtM, YanS: Case records of the Massachusetts General Hospital. Case 7-2007. A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med356: 1049–1057, 2007PubMed
BazariH, JaffMR, MannstadtM, YanS: Case records of the Massachusetts General Hospital. Case 7-2007. A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med 356: 1049–1057, 2007PubMed)| false
BaldwinC, FarahM, LeungM, TaylorP, WerbR, KiaiiM, et al.: Multi-intervention management of calciphylaxis: A report of 7 cases. Am J Kidney Dis58: 988–991, 2011PubMed
BaldwinC, FarahM, LeungM, TaylorP, WerbR, KiaiiM, et al.: Multi-intervention management of calciphylaxis: A report of 7 cases. Am J Kidney Dis 58: 988–991, 2011PubMed)| false
UdomkarnjananunS, KongnatthasateK, PraditpornsilpaK, Eiam-OngS, JaberBL, SusantitaphongP: Treatment of calciphylaxis in CKD: A systematic review and meta-analysis. Kidney Int Rep4: 231–244, 2018PubMed
UdomkarnjananunS, KongnatthasateK, PraditpornsilpaK, Eiam-OngS, JaberBL, SusantitaphongP: Treatment of calciphylaxis in CKD: A systematic review and meta-analysis. Kidney Int Rep 4: 231–244, 2018PubMed)| false
ChinnaduraiR, SinhaS, LowneyAC, MillerM: Pain management in patients with end-stage renal disease and calciphylaxis: A survey of clinical practices among physicians. BMC Nephrol21: 403, 2020PubMed
ChinnaduraiR, SinhaS, LowneyAC, MillerM: Pain management in patients with end-stage renal disease and calciphylaxis: A survey of clinical practices among physicians. BMC Nephrol 21: 403, 2020PubMed)| false
MachS, CollieMA, PesceMB: Palliative nerve block for penile calciphylaxis: A case report on ultrasound-guided phenol neurolysis. A A Pract15: e01416, 2021PubMed
MachS, CollieMA, PesceMB: Palliative nerve block for penile calciphylaxis: A case report on ultrasound-guided phenol neurolysis. A A Pract 15: e01416, 2021PubMed)| false
OrtegaMA, Fraile-MartinezO, García-MonteroC, Callejón-PeláezE, SáezMA, Álvarez-MonMA, et al.: A General overview on the hyperbaric oxygen therapy: Applications, mechanisms and translational opportunities. Medicina (Kaunas)57: 864, 2021PubMed
OrtegaMA, Fraile-MartinezO, García-MonteroC, Callejón-PeláezE, SáezMA, Álvarez-MonMA, et al.: A General overview on the hyperbaric oxygen therapy: Applications, mechanisms and translational opportunities. Medicina (Kaunas) 57: 864, 2021PubMed)| false
DonBR, ChinAI: A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol59: 463–470, 2003PubMed
DonBR, ChinAI: A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 59: 463–470, 2003PubMed)| false
López MartínezJA, Rodríguez ValienteM, Fuente-MoraC, García-HernándezAM, Cánovas SanchísS, Fernández PascualCJ: Use of cryopreserved human amniotic membrane in the treatment of skin ulcers secondary to calciphylaxis. Dermatol Ther (Heidelb)34: e14769, 2021PubMed
López MartínezJA, Rodríguez ValienteM, Fuente-MoraC, García-HernándezAM, Cánovas SanchísS, Fernández PascualCJ: Use of cryopreserved human amniotic membrane in the treatment of skin ulcers secondary to calciphylaxis. Dermatol Ther (Heidelb) 34: e14769, 2021PubMed)| false
AmuluruL, HighW, HiattKM, RanvilleJ, ShahSV, MalikB, et al.: Metal deposition in calcific uremic arteriolopathy. J Am Acad Dermatol61: 73–79, 2009PubMed
AmuluruL, HighW, HiattKM, RanvilleJ, ShahSV, MalikB, et al.: Metal deposition in calcific uremic arteriolopathy. J Am Acad Dermatol 61: 73–79, 2009PubMed)| false
OgataH, FukagawaM, HirakataH, KagimuraT, FukushimaM, AkizawaT; LANDMARK Investigators and Committees: Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA325: 1946–1954, 2021PubMed
OgataH, FukagawaM, HirakataH, KagimuraT, FukushimaM, AkizawaT; LANDMARK Investigators and Committees: Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA 325: 1946–1954, 2021PubMed)| false
IsakaY, HamanoT, FujiiH, TsujimotoY, KoiwaF, SakaguchiY, et al.: Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol32: 723–735, 2021PubMed
IsakaY, HamanoT, FujiiH, TsujimotoY, KoiwaF, SakaguchiY, et al.: Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol 32: 723–735, 2021PubMed)| false
Garza-MayersAC, ShahR, SykesDB, NigwekarSU, KroshinskyD: The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: A retrospective analysis. Am J Nephrol48: 168–171, 2018PubMed
Garza-MayersAC, ShahR, SykesDB, NigwekarSU, KroshinskyD: The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: A retrospective analysis. Am J Nephrol 48: 168–171, 2018PubMed)| false
KingBJ, El-AzharyRA, McEvoyMT, ShieldsRC, McBaneRD, McCarthyJT, et al.: Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol56: 1065–1070, 2017PubMed
KingBJ, El-AzharyRA, McEvoyMT, ShieldsRC, McBaneRD, McCarthyJT, et al.: Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol 56: 1065–1070, 2017PubMed)| false
ZittE, KönigM, VychytilA, AuingerM, WallnerM, LingenhelG, et al.: Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant28: 1232–1240, 2013PubMed
ZittE, KönigM, VychytilA, AuingerM, WallnerM, LingenhelG, et al.: Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant 28: 1232–1240, 2013PubMed)| false
WenW, Portales-CastilloI, SeethapathyR, et al.: Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients: A systematic review and meta-analysis. Nephrol Dial Transplant38: 733–745, 2023
WenW, Portales-CastilloI, SeethapathyR, et al.: Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients: A systematic review and meta-analysis. Nephrol Dial Transplant 38: 733–745, 2023)| false
HundemerGL, FenvesAZ, PhillipsKM, EmmettM: Sodium thiosulfate and the anion gap in patients treated by hemodialysis. Am J Kidney Dis68: 499–500, 2016PubMed
HundemerGL, FenvesAZ, PhillipsKM, EmmettM: Sodium thiosulfate and the anion gap in patients treated by hemodialysis. Am J Kidney Dis 68: 499–500, 2016PubMed)| false
SinghRP, DerendorfH, RossEA: Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol6: 1155–1159, 2011PubMed
SinghRP, DerendorfH, RossEA: Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 6: 1155–1159, 2011PubMed)| false
YangX, LiuY, XieX, ShiW, SiJ, LiX, et al.: Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients. Ren Fail44: 914–922, 2022PubMed
YangX, LiuY, XieX, ShiW, SiJ, LiX, et al.: Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients. Ren Fail 44: 914–922, 2022PubMed)| false
ArayaCE, FennellRS, NeibergerRE, DharnidharkaVR: Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol1: 1161–1166, 2006PubMed
ArayaCE, FennellRS, NeibergerRE, DharnidharkaVR: Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 1: 1161–1166, 2006PubMed)| false
BrandenburgVM, SinhaS, TorregrosaJV, GargR, MillerS, CanalsAZ, et al.: Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: A phase 2 open-label study of patients with calciphylaxis. J Nephrol32: 811–821, 2019PubMed
BrandenburgVM, SinhaS, TorregrosaJV, GargR, MillerS, CanalsAZ, et al.: Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: A phase 2 open-label study of patients with calciphylaxis. J Nephrol 32: 811–821, 2019PubMed)| false
SinhaS, GouldLJ, NigwekarSU, SerenaTE, BrandenburgV, MoeSM, et al.: The CALCIPHYX study: A randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J15: 136–144, 2021PubMed
SinhaS, GouldLJ, NigwekarSU, SerenaTE, BrandenburgV, MoeSM, et al.: The CALCIPHYX study: A randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. Clin Kidney J 15: 136–144, 2021PubMed)| false
RaggiP, BellasiA, BushinskyD, BoverJ, RodriguezM, KettelerM, et al.: Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: Results of a randomized phase 2b study. Circulation141: 728–739, 2020PubMed
RaggiP, BellasiA, BushinskyD, BoverJ, RodriguezM, KettelerM, et al.: Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: Results of a randomized phase 2b study. Circulation 141: 728–739, 2020PubMed)| false
el-AzharyRA, ArthurAK, DavisMD, McEvoyMT, GibsonLE, WeaverAL, et al.: Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol149: 63–67, 2013PubMed
el-AzharyRA, ArthurAK, DavisMD, McEvoyMT, GibsonLE, WeaverAL, et al.: Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol 149: 63–67, 2013PubMed)| false
SanguankeoA, ThamcharoenN, UpalaS: WITHDRAWN: Calciphylaxis in a nondialysis patient treated with sodium thiosulfate and high dose of oxygen. Clin Nephrol5: 38–41, 2017PubMed
SanguankeoA, ThamcharoenN, UpalaS: WITHDRAWN: Calciphylaxis in a nondialysis patient treated with sodium thiosulfate and high dose of oxygen. Clin Nephrol 5: 38–41, 2017PubMed)| false
LevyR: Potential treatment of calciphylaxis with vitamin K(2): Comment on the article by Jacobs-Kosmin and DeHoratius. Arthritis Rheum57: 1575–1576, 2007PubMed
LevyR: Potential treatment of calciphylaxis with vitamin K(2): Comment on the article by Jacobs-Kosmin and DeHoratius. Arthritis Rheum 57: 1575–1576, 2007PubMed)| false
ZakherM, ChaudhryRI, MonrroyM, et al.: Clinical characteristics and outcomes of patients with calciphylaxis. Am J Med Sci361; 132–134, 2021PubMed
ZakherM, ChaudhryRI, MonrroyM, et al.: Clinical characteristics and outcomes of patients with calciphylaxis. Am J Med Sci 361; 132–134, 2021PubMed)| false
WithamMD, LeesJS, WhiteM, BandM, BellS, ChantlerDJ, et al.: Vitamin K supplementation to improve vascular stiffness in CKD: The K4Kidneys randomized controlled trial. J Am Soc Nephrol31: 2434–2445, 2020PubMed
WithamMD, LeesJS, WhiteM, BandM, BellS, ChantlerDJ, et al.: Vitamin K supplementation to improve vascular stiffness in CKD: The K4Kidneys randomized controlled trial. J Am Soc Nephrol 31: 2434–2445, 2020PubMed)| false
RobertT, LionetA, BatailleS, SeretG: Rheopheresis: A new therapeutic approach in severe calciphylaxis. Nephrology (Carlton)25: 298–304, 2020PubMed
RobertT, LionetA, BatailleS, SeretG: Rheopheresis: A new therapeutic approach in severe calciphylaxis. Nephrology (Carlton) 25: 298–304, 2020PubMed)| false
CoyneDW, SinghHN, SmithWT, GiuseppiAC, ConnarnJN, ShermanML, et al.: Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. Kidney Int Rep4: 1585–1597, 2019PubMed
CoyneDW, SinghHN, SmithWT, GiuseppiAC, ConnarnJN, ShermanML, et al.: Sotatercept safety and effects on hemoglobin, bone, and vascular calcification. Kidney Int Rep 4: 1585–1597, 2019PubMed)| false
O’NeilB, SouthwickAW: Three cases of penile calciphylaxis: diagnosis, treatment strategies, and the role of sodium thiosulfate. Urology80: 5–8, 2012PubMed
O’NeilB, SouthwickAW: Three cases of penile calciphylaxis: diagnosis, treatment strategies, and the role of sodium thiosulfate. Urology 80: 5–8, 2012PubMed)| false
OlaniranKO, PercySG, ZhaoS, BlaisC, JacksonV, KamdarMM, et al.: Palliative care use and patterns of end-of-life care in hospitalized patients with calciphylaxis. J Pain Symptom Manage57: e1–e3, 2019PubMed
OlaniranKO, PercySG, ZhaoS, BlaisC, JacksonV, KamdarMM, et al.: Palliative care use and patterns of end-of-life care in hospitalized patients with calciphylaxis. J Pain Symptom Manage 57: e1–e3, 2019PubMed)| false
